78.02 0.00 (0.00%)
After hours: 4:34PM EDT
|Bid||78.20 x 900|
|Ask||78.11 x 800|
|Day's Range||77.72 - 78.88|
|52 Week Range||51.51 - 82.55|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||66.29|
|Earnings Date||Oct 21, 2020 - Oct 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.47|
Edwards Lifesciences handily topped Wall Street's second-quarter expectations amid a resurgence in heart-valve replacements. EW stock inched slightly closer to a buy point Friday.
In the current session, Edwards Lifesciences Inc. (NYSE: EW) is trading at $77.38, after a 0.05% rise. Over the past month, the stock increased by 20.14%, and in the past year, by 11.87%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 68.75%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.View more earnings on EWMost often, an industry will prevail in a particular phase of a business cycle, than other industries.Edwards Lifesciences Inc. has a lower P/E than the aggregate P/E of 150.61 of the Medical Devices industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Edwards Lifesciences: Q2 Earnings Insights * Earnings Scheduled For July 23, 2020 * Stocks That Hit 52-Week Lows On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
Investors might not be overly excited about Edwards Lifesciences' (NYSE: EW) stock performance so far in 2020. Edwards Lifesciences announced its second-quarter results after the market closed on Thursday, and the stock jumped 5% in after-hours trading.
With me on today's call are Mike Mussallem, Chairman and Chief Executive Officer and Scott Ullem Chief Financial Officer. Just after the close of regular trading, Edwards Lifesciences released second quarter 2020 financial results.
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Edwards Lifesciences (NYSE:EW) moved higher by 3.5% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 75.36% year over year to $0.34, which beat the estimate of $0.17.Revenue of $925,000,000 declined by 14.90% year over year, which beat the estimate of $789,420,000.Looking Ahead The upcoming fiscal year's EPS expected to be between $1.75 and $1.95.Q3 revenue expected between $4,000,000,000 and $4,500,000,000.Details Of The Call Date: Jul 23, 2020View more earnings on EWTime: 05:00 PMET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1335563&tp_key=cabc10f160Technicals 52-week high: $247.6452-week low: $66.23Price action over last quarter: Up 8.39%Company Overview Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.See more from Benzinga * Earnings Scheduled For July 23, 2020 * Stocks That Hit 52-Week Lows On Friday * Stocks That Hit 52-Week Lows On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Late Thursday, Edwards Lifesciences reported adjusted income of 34 cents per share on $925 million in sales for its second quarter ended June 30. In response, EW stock popped.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2020.
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Large-Cap Growth Fund posted a return of 27.86% for the quarter, outperforming its benchmark, the Russell 1000 Growth Index which returned 27.84% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Most readers would already be aware that Edwards Lifesciences' (NYSE:EW) stock increased significantly by 9.3% over...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Paul A. LaViolette has been appointed to its board of directors. LaViolette has 40 years of experience in global medical technology, operating leadership and investing, serving in executive-level roles at companies including Boston Scientific Corp. and C.R. Bard Inc.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it received approval from the U.S. Food and Drug Administration (FDA) for the KONECT RESILIA aortic valved conduit (AVC), the first ready-to-implant solution for bio-Bentall procedures, a complex surgery that involves replacement of a patient's aortic valve, aortic root and the ascending aorta.
Abbott Laboratories and Edwards Lifesciences Corp. said late Monday they settled a patent dispute with each other over certain heart valve repair products. The two medical device makers have been embroiled in a legal dispute for more than a year over whether Edwards's Pascal valve products infringe the patents of Abbott's MitraClip products. While both companies said details of the 10-year agreement were confidential, Edwards said it will book a one-time settlement expense in the June-ending quarter and will pay royalties to Abbott through May 2024. Abbott said it will receive a one-time payment and "ongoing payments" based on Pascal sales through 2025 along with a possible milestone payment in 2026.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has reached an agreement with Abbott to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. Edwards considers this agreement a positive development, as it allows the company to fully dedicate time and resources to helping patients.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended June 30, 2020 after the market closes on Thursday, July 23, 2020, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...